{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:41:13Z","timestamp":1786995673783,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council, Taiwan","doi-asserted-by":"crossref","award":["NSC97-2320-B-320-002-MY3"],"award-info":[{"award-number":["NSC97-2320-B-320-002-MY3"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.pharep.2018.01.003","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T13:27:50Z","timestamp":1515763670000},"page":"668-676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson\u2019s disease"],"prefix":"10.1007","volume":"70","author":[{"given":"Hwei-Hsien","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinpiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Huan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"1","key":"10.1016\/j.pharep.2018.01.003_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mds.25150","article-title":"Parkinson\u2019s disease: evidence for environmental risk factors","volume":"28","author":"Kieburtz","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharep.2018.01.003_bib0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.neuro.22.1.123","article-title":"Etiology and pathogenesis of Parkinson\u2019s disease","volume":"22","author":"Olanow","year":"1999","journal-title":"Annu Rev Neurosci"},{"issue":"8","key":"10.1016\/j.pharep.2018.01.003_bib0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S1474-4422(04)00823-3","article-title":"Neuroprotection and pharmacotherapy for motor symptoms in Parkinson\u2019s disease","volume":"3","author":"Clarke","year":"2004","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.pharep.2018.01.003_bib0020","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2014.931369","article-title":"Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson\u2019s disease","volume":"13","author":"Faulkner","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.pharep.2018.01.003_bib0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1440-1819.2000.00756.x","article-title":"Effectiveness of the Kampo kami-shoyo-san (TJ-24) for tremor of antipsychotic-induced parkinsonism","volume":"54","author":"Ishikawa","year":"2000","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pharep.2018.01.003_bib0030","doi-asserted-by":"crossref","first-page":"724353","DOI":"10.1093\/ecam\/nep116","article-title":"Treatment of idiopathic Parkinson\u2019s disease with traditional chinese herbal medicine: a randomized placebo-controlled pilot clinical study","volume":"2011","author":"Kum","year":"2011","journal-title":"Evid Based Complement Altern Med"},{"issue":"3","key":"10.1016\/j.pharep.2018.01.003_bib0035","first-page":"165","article-title":"Anchanling reduces pathology in a lactacystin- induced Parkinson\u2019s disease model","volume":"7","author":"Li","year":"2012","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.003_bib0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1021\/np9702446","article-title":"Identification of magnolol and honokiol as anxiolytic agents in extracts of saiboku-to, an oriental herbal medicine","volume":"61","author":"Maruyama","year":"1998","journal-title":"J Nat Prod"},{"issue":"4","key":"10.1016\/j.pharep.2018.01.003_bib0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.neuropharm.2005.04.009","article-title":"Differential inhibitory effects of honokiol and magnolol on excitatory amino acid-evoked cation signals and NMDA-induced seizures","volume":"49","author":"Lin","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharep.2018.01.003_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1742-2094-10-15","article-title":"Magnolia polyphenols attenuate oxidative and inflammatory responses in neurons and microglial cells","volume":"10","author":"Chuang","year":"2013","journal-title":"J Neuroinflammation"},{"issue":"5","key":"10.1016\/j.pharep.2018.01.003_bib0055","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000323872","article-title":"Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism","volume":"8","author":"Chen","year":"2011","journal-title":"Neurodegener Dis"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.003_bib0060","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bmcl.2011.11.030","article-title":"An expedient synthesis of honokiol and its analogues as potential neuropreventive agents","volume":"22","author":"Tripathi","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"10.1016\/j.pharep.2018.01.003_bib0065","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1007\/s11064-008-9697-6","article-title":"Role of nitric oxide synthases in Parkinson\u2019s disease: a review on the antioxidant and anti-inflammatory activity of polyphenols","volume":"33","author":"Aquilano","year":"2008","journal-title":"Neurochem Res"},{"issue":"2","key":"10.1016\/j.pharep.2018.01.003_bib0070","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3892\/etm.2014.2099","article-title":"Excessive levels of nitric oxide in rat model of Parkinson\u2019s disease induced by rotenone","volume":"9","author":"Xiong","year":"2015","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.003_bib0075","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.expneurol.2007.10.012","article-title":"Characterization of the striatal 6-OHDA model of Parkinson\u2019s disease in wild type and alpha-synuclein-deleted mice","volume":"210","author":"Alvarez-Fischer","year":"2008","journal-title":"Exp Neurol"},{"issue":"76","key":"10.1016\/j.pharep.2018.01.003_bib0080","doi-asserted-by":"crossref","DOI":"10.3791\/50303","article-title":"Assessment of sensorimotor function in mouse models of Parkinson\u2019s disease","author":"Fleming","year":"2013","journal-title":"J Vis Exp"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.003_bib0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","article-title":"Classic toxin-induced animal models of Parkinson\u2019s disease: 6-OHDA and MPTP","volume":"318","author":"Schober","year":"2004","journal-title":"Cell Tissue Res"},{"issue":"8","key":"10.1016\/j.pharep.2018.01.003_bib0090","doi-asserted-by":"crossref","first-page":"e70951","DOI":"10.1371\/journal.pone.0070951","article-title":"Activation of GSK-3beta and caspase-3 occurs in nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine","volume":"8","author":"Hernandez-Baltazar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharep.2018.01.003_bib0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2014.09.033","article-title":"Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinsons disease","volume":"1589","author":"Morroni","year":"2014","journal-title":"Brain Res"},{"key":"10.1016\/j.pharep.2018.01.003_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2013.07.005","article-title":"Neuronal nicotinic receptor agonists ameliorate spontaneous motor asymmetries and motor discoordination in a unilateral mouse model of Parkinson\u2019s disease","volume":"111","author":"Kucinski","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"10.1016\/j.pharep.2018.01.003_bib0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02741387","article-title":"Tyrosine hydroxylase and Parkinson\u2019s disease","volume":"16","author":"Haavik","year":"1998","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.003_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2005.02.023","article-title":"Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson\u2019s disease in mice","volume":"162","author":"Iancu","year":"2005","journal-title":"Behav Brain Res"},{"issue":"3","key":"10.1016\/j.pharep.2018.01.003_bib0115","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0306-4522(95)00066-R","article-title":"Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine","volume":"67","author":"Przedborski","year":"1995","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.pharep.2018.01.003_bib0120","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1248\/bpb.b13-00537","article-title":"Neuroprotective effect of trans-cinnamaldehyde on the 6-hydroxydopamine-induced dopaminergic injury","volume":"36","author":"Pyo","year":"2013","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"10.1016\/j.pharep.2018.01.003_bib0125","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1046\/j.1471-4159.2000.0741605.x","article-title":"Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson\u2019s disease","volume":"74","author":"Soto-Otero","year":"2000","journal-title":"J Neurochem"},{"issue":"6","key":"10.1016\/j.pharep.2018.01.003_bib0130","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jnr.20599","article-title":"Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson\u2019s disease","volume":"81","author":"Okuno","year":"2005","journal-title":"J Neurosci Res"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.003_bib0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0306-4522(01)00562-0","article-title":"Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration","volume":"110","author":"Iravani","year":"2002","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.003_bib0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/molecules20010293","article-title":"Protective effects of Lycium barbarum polysaccharide on 6-OHDA-induced apoptosis in PC12 cells through the ROS-NO pathway","volume":"20","author":"Gao","year":"2014","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.pharep.2018.01.003_bib0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1179\/135100005X38842","article-title":"Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson\u2019s disease","volume":"10","author":"Singh","year":"2005","journal-title":"Redox Rep"},{"key":"10.1016\/j.pharep.2018.01.003_bib0150","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuroscience.2015.01.047","article-title":"Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion","volume":"290","author":"Ramirez-Garcia","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharep.2018.01.003_bib0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2013.10.011","article-title":"Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine","volume":"1541","author":"Czarnecka","year":"2013","journal-title":"Brain Res"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017302931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017302931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:30Z","timestamp":1752611850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2018.01.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1734114017302931"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2018.01.003","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2018.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}